Company Overview

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and related diseases through oncolytic virus platforms and immuno-oncology approaches. The company operates primarily within the biotechnology and biopharmaceutical industries, with a concentration on therapies designed to selectively target tumor cells while stimulating anti-tumor immune responses. Theriva’s principal development programs have included the investigational oncolytic adenovirus candidate VCN-01, as well as earlier-stage therapeutic and vaccine-related research initiatives. The company’s revenue profile has historically been limited because it remains in the clinical development stage and has not commercialized a product approved for broad market sale.

Theriva Biologics evolved from earlier biotechnology operations conducted under the name Synthetic Biologics, Inc. before rebranding to reflect a strategic emphasis on oncology and viral immunotherapy. The company’s positioning has centered on the development of tumor-selective viral therapies designed to improve delivery into solid tumors and potentially enhance the effectiveness of existing cancer treatments. Its strategic differentiation has been tied to intellectual property surrounding adenoviral platforms engineered for tumor penetration and immune activation in difficult-to-treat cancers such as pancreatic cancer and retinoblastoma.

Business Operations

Theriva Biologics conducts operations primarily through research and clinical development activities rather than commercial manufacturing or large-scale product sales. Its core business activities include preclinical research, clinical trial management, regulatory engagement, intellectual property development, and strategic collaboration activities. The company’s principal operating focus has been its oncolytic adenovirus platform, particularly VCN-01, which has been studied in combination with chemotherapy and immune-based treatment approaches in solid tumor indications. Theriva has historically relied on equity financing, licensing arrangements, and strategic collaborations to fund operations.

The company’s operational footprint has included activities in both the United States and Europe, particularly through relationships connected to clinical development and technology licensing. Theriva has maintained collaborations with academic institutions, clinical research organizations, and biotechnology partners involved in oncology research. Certain development and manufacturing activities have involved external specialized providers rather than fully integrated in-house production infrastructure. Data inconclusive based on available public sources regarding the current status of all historical partnerships and development-stage subsidiaries.

Strategic Position & Investments

Theriva’s strategic direction has focused on advancing viral immunotherapy candidates through clinical-stage development while exploring combination treatment opportunities with existing oncology therapies. The company has emphasized indications with significant unmet medical need, particularly aggressive or treatment-resistant solid tumors. Its development strategy has included evaluating how oncolytic viruses may improve tumor penetration, increase immune activation, and potentially enhance responses to checkpoint inhibitors or chemotherapy regimens.

A significant strategic transaction in the company’s history involved the acquisition of rights associated with the VCN Biosciences platform and related intellectual property tied to the VCN-01 program. Theriva has also pursued capital-raising initiatives intended to sustain clinical development and regulatory activities. Emerging areas of focus have included precision oncology applications and immunotherapy combinations, although the company remains dependent on clinical trial outcomes, regulatory progress, and financing access to support long-term commercialization objectives.

Geographic Footprint

Theriva Biologics is headquartered in the United States, with corporate operations historically based in Maryland. The company’s clinical and research activities have involved collaborations and development efforts extending into Europe, particularly through relationships connected to adenovirus platform technologies and oncology trial execution. Its operational reach has therefore been international despite its relatively small corporate scale.

The company’s market and investment exposure are primarily concentrated in the North American biotechnology sector, though clinical development partnerships and scientific collaborations have provided visibility in select European markets. Theriva does not currently operate as a large multinational commercial pharmaceutical company, and its international presence is primarily tied to research, licensing, and clinical development activities rather than broad product distribution networks.

Leadership & Governance

Theriva Biologics has been led by executives with backgrounds in biotechnology development, finance, and clinical-stage pharmaceutical operations. Leadership strategy has emphasized advancing differentiated oncology platforms through disciplined clinical development while seeking partnerships capable of supporting commercialization and broader market access. As a publicly traded biotechnology company, Theriva is governed by a board of directors responsible for oversight of corporate strategy, financing, and regulatory compliance.

Key executives and leadership figures have included:

• Steven A. Shallcross – Chief Executive Officer
• James E. Frakes – Vice President, Finance
• Robert E. Lee – Chairman of the Board

Data inconclusive based on available public sources regarding the complete current executive roster and any recent leadership changes beyond publicly disclosed filings and investor materials.